Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Professor Sarah Gilbert has been awarded the Royal Society for Arts, Manufactures and Commerce’ (RSA) Albert Medal for her work on the Oxford vaccine.

Oxford skyline and Radcliffe Camera © Oxford University Images / Whitaker Studio

The lead researcher on the Oxford vaccine team, Professor Sarah Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the world.

The RSA Albert Medal is awarded annually to recognise the creativity and innovation of individuals and organisations working to resolve the challenges of our time. Professor Gilbert receives the 2021 honour for her services to collaborative innovation for the global common good. She is the 156th recipient of the medal, which was instituted in 1864 as a memorial to Prince Albert, former President of the Society.

Previous recipients range from scientists to artists to social campaigners: they include Alexander Graham Bell in 1902 for the invention of the telephone; Marie Curie in 1910 for the discovery of radium; Stephen Hawking in 1999 for improving public awareness of physics; and Tim Berners-Lee in 2002 for the creation of the World Wide Web.

Read the full story on the University of Oxford website.

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.